Evidence map›Paper›PMID 30978984›Full record

ReviewCells2019

Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging.

Prasanta Dutta, Travis C Salzillo, Shivanand Pudakalakatti, Seth T Gammon, Benny A Kaipparettu, Florencia McAllister, Shawn Wagner, Daniel E Frigo, Christopher J Logothetis, Niki M Zacharias and 1 more

Abstract readReview
In one paragraph

Review in Cells, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Identifying the Metabolic Signatures of PPARD-Overexpressing Gastric Tumors.International journal of molecular sciences · 2022
    Article
  9. Metabolic Imaging Using Hyperpolarization for Assessment of Premalignancy.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Hyperpolarized [1-Proceedings of the National Academy of Sciences of the United States of America · 2020
    Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Prasanta DuttaDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. pdutta@mdanderson.org.
Travis C SalzilloDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. TCSalzillo@mdanderson.org.
Shivanand PudakalakattiDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. SPudakalakatti@mdanderson.org.
Seth T GammonDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. STGammon@mdanderson.org.
Benny A KaipparettuDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA. kaippare@bcm.edu.
Florencia McAllisterDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. FMcAllister@mdanderson.org.
Shawn WagnerBiomedical Imaging Research Institute Cedars Sinai Medical Center, Los Angeles, CA 90048, USA. shawn.wagner@cshs.org.
Daniel E FrigoDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Frigo@mdanderson.org.
Christopher J LogothetisDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. clogothe@mdanderson.org.
Niki M ZachariasDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. NMZacharias@mdanderson.org.
Pratip K BhattacharyaDepartment of Cancer Systems Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. pkbhattacharya@mdanderson.org.ORCID 0000-0002-0625-252X

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
WU-MDACC Inter-Institutional Molecular Imaging CenterP50CA094056 · NCI · WASHINGTON UNIVERSITY · PI PIWNICA-WORMS, DAVID · 2002 to 2016
$26.3M
Paul Calabresi Clinical Oncology AwardK12CA088084 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI David S. Hong, Scott Kopetz · 2000 to 2026
$14.0M
Texas Center for Cancer NanomedicineU54CA151668 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CRISTINI, VITTORIO, FERRARI, MAURO · 2010 to 2014
$12.4M
ENERGY REPROGRAMMING-REGULATED ONCOPATHWAYS AND DRUG RESISTANCE IN TRIPLE NEGATIVE BREAST CANCERR01CA234479 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KAIPPARETTU, BENNY ABRAHAM · 2019 to 2023
$2.4M
Development of SUPR peptides as PET Imaging Agents for Her2+ Breast CancerR44CA206771 · NCI · EVORX TECHNOLOGIES, INC. · PI FIACCO, STEPHEN, MILLWARD, STEVEN W · 2016 to 2018
$2.0M
Genetic & Metabolic Dissection of the CaMKKbeta Signaling Axis in Prostate CancerR01CA184208 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FRIGO, DANIEL EDWARD · 2015 to 2019
$1.9M
Targeted Molecular Imaging of Cell Death in Ovarian CancerR21CA181994 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LU, ZHEN, MILLWARD, STEVEN W · 2016 to 2017
$383k
(PQC5)Early Detection Pancreatic Cancer by Hyperpolarized Silicon NanoparticlesR21CA185536 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BHATTACHARYA, PRATIP K. · 2014 to 2015
$383k
High-fat diet-mediated activation of Src oncopathway in triple negative breast cancerR03CA235113 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KAIPPARETTU, BENNY ABRAHAM · 2019 to 2020
$159k
Mitochondrial DNA copy number and fat metabolism in triple negative breast cancerR03CA212816 · NCI · BAYLOR COLLEGE OF MEDICINE · PI KAIPPARETTU, BENNY ABRAHAM · 2017 to 2018
$159k
NCI NIH HHS P30 CA016672NCI NIH HHS P50 CA094056NCI NIH HHS R01 CA184208NCI NIH HHS R01 CA234479NCI NIH HHS R03 CA212816NCI NIH HHS R03 CA235113NCI NIH HHS R21 CA181994NCI NIH HHS R21 CA185536NCI NIH HHS R44 CA206771NCI NIH HHS U54 CA151668
6 · The paper itself

Abstract

Precisely measuring tumor-associated alterations in metabolism clinically will enable the efficient assessment of therapeutic responses. Advances in imaging technologies can exploit the differences in cancer-associated cell metabolism as compared to normal tissue metabolism, linking changes in target metabolism to therapeutic efficacy. Metabolic imaging by Positron Emission Tomography (PET) employing 2-fluoro-deoxy-glucose ([

Indexed as

NeoplasmsOutcome and Process Assessment, Health CareAnimalsCarbon IsotopesCell LineHumansMagnetic Resonance ImagingMicePyruvic AcidRatsCarbon-13Carbon IsotopesPyruvic Acidcancer metabolismhyperpolarizationmetabolic imagingMRItherapy monitoring

Identifiers

PMID30978984
PMCPMC6523855

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.